Armata PharmaceuticalsARMP
About: Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Employees: 75
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.01% more ownership
Funds ownership: 3.82% [Q3] → 3.84% (+0.01%) [Q4]
0% more funds holding
Funds holding: 23 [Q3] → 23 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
22% less capital invested
Capital invested by funds: $3.28M [Q3] → $2.57M (-$710K) [Q4]
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $22K
Research analyst outlook
We haven’t received any recent analyst ratings for ARMP.
Financial journalist opinion
Based on 3 articles about ARMP published over the past 30 days









